Phase 4
N=12
The Role of COX-2 Inhibition in Salt Sensitivity of Blood Pressure
Hypertension
Bottom Line
View on ClinicalTrials.gov: NCT00624559 ↗Enrolled (actual)
12
Serious AEs
0.0%
Results posted
Dec 2011
Primary outcome: Primary: Mean Arterial Pressure — 88; 87; 87; 87 mm Hg
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- celecoxib (Celebrex) (Drug); Placebo (Other)
- Age
- Adult · 22+ yrs
- Sex
- All
- Sponsor
- University of Delaware
- Primary completion
- Jan 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Arterial Pressure |
88; 87; 87; 87 | — |
| SECONDARY Urinary Sodium Excretion |
17; 281; 14; 253 | — |
Summary
The purpose of this study is to determine if the drug Celebrex changes the way the kidney gets rid of salt and maintains blood pressure.
Eligibility Criteria
Inclusion Criteria
- healthy men and women
Exclusion Criteria
- history of heart disease
- have had heart surgery
- high blood pressure
- diabetes
- cancer
- any other disease such as kidney or neurological diseases
- taking medications such as aspirin or medicines for your heart or blood pressure
- have asthma or are allergic to sulfa drugs
- body mass index greater than 30
- use tobacco
- pregnant
- women using oral contraceptives or hormone replacement therapy
Data sourced from ClinicalTrials.gov (NCT00624559). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.